VEGF-A Inhibition as a Potential Therapeutic Approach in Merkel Cell Carcinoma

J Invest Dermatol. 2019 Mar;139(3):736-739. doi: 10.1016/j.jid.2018.08.029. Epub 2018 Oct 22.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Merkel Cell / drug therapy*
  • Female
  • Humans
  • Immunohistochemistry
  • Immunotherapy / trends*
  • Mice
  • Mice, Inbred NOD
  • Neoplasm Staging
  • Skin Neoplasms / drug therapy*
  • Tissue Array Analysis
  • Tumor Microenvironment
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vascular Endothelial Growth Factor A / genetics
  • Vascular Endothelial Growth Factor A / metabolism*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • avelumab